Abbott Laboratories $ABT Stock Position Increased by Wormser Freres Gestion

Wormser Freres Gestion lifted its position in Abbott Laboratories (NYSE:ABT) by 1,798.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,968 shares of the healthcare product maker’s stock after buying an additional 6,601 shares during the period. Abbott Laboratories makes up 0.5% of Wormser Freres Gestion’s holdings, making the stock its 22nd largest position. Wormser Freres Gestion’s holdings in Abbott Laboratories were worth $873,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in shares of Abbott Laboratories by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after buying an additional 2,402,408 shares in the last quarter. Capital International Investors grew its holdings in shares of Abbott Laboratories by 2.5% during the third quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock valued at $8,251,974,000 after buying an additional 1,478,076 shares in the last quarter. Norges Bank purchased a new position in shares of Abbott Laboratories during the fourth quarter valued at $2,938,892,000. Invesco Ltd. grew its stake in Abbott Laboratories by 51.0% in the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock valued at $1,868,718,000 after purchasing an additional 4,713,135 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its stake in Abbott Laboratories by 3.8% in the third quarter. Ameriprise Financial Inc. now owns 13,500,829 shares of the healthcare product maker’s stock valued at $1,804,050,000 after purchasing an additional 499,351 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott recently secured FDA and EU approval for its AI-powered Ultreon 3.0 tool, which could support growth in its cardiovascular imaging business and add to its medical technology momentum. Article Title
• Positive Sentiment: Abbott also obtained CE mark clearance for its Libre Duo glucose-ketone monitor, expanding its diabetes technology lineup and reinforcing innovation in one of its key growth categories. Article Title
• Neutral Sentiment: Recent coverage highlighting strong Wall Street views on Abbott suggests analysts remain constructive on the stock’s long-term prospects, but the articles do not point to a new upgrade or a near-term earnings catalyst. Article Title
• Neutral Sentiment: Zacks noted that investors have been searching for Abbott more heavily, which can reflect increased interest, but does not by itself change the company’s fundamentals. Article Title
• Negative Sentiment: One comparison piece argued Boston Scientific may offer more upside than Abbott, which can weigh on ABT sentiment by implying investors may prefer a rival medtech name right now. Article Title

Abbott Laboratories Stock Performance

ABT opened at $85.36 on Friday. The company has a market cap of $148.68 billion, a PE ratio of 23.91, a price-to-earnings-growth ratio of 1.43 and a beta of 0.65. The stock has a 50-day moving average of $94.46 and a 200-day moving average of $110.69. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $139.06. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter in the prior year, the company earned $1.09 EPS. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities research analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Insider Activity

In related news, VP John A. Jr. Mccoy sold 585 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the sale, the vice president owned 24,628 shares in the company, valued at $2,846,504.24. This represents a 2.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were acquired at an average price of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director owned 6,751,103 shares in the company, valued at $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold 3,055 shares of company stock worth $353,097 over the last 90 days. Company insiders own 0.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on ABT shares. Bank of America lowered their target price on Abbott Laboratories from $150.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Argus cut their price objective on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, April 21st. TD Cowen cut their price objective on shares of Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Citigroup cut their price objective on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Finally, Weiss Ratings lowered shares of Abbott Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, April 24th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $119.09.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.